HRP20160373T1 - Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava - Google Patents

Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava Download PDF

Info

Publication number
HRP20160373T1
HRP20160373T1 HRP20160373TT HRP20160373T HRP20160373T1 HR P20160373 T1 HRP20160373 T1 HR P20160373T1 HR P20160373T T HRP20160373T T HR P20160373TT HR P20160373 T HRP20160373 T HR P20160373T HR P20160373 T1 HRP20160373 T1 HR P20160373T1
Authority
HR
Croatia
Prior art keywords
use according
combination
physiologically acceptable
pharmaceutical
treatment
Prior art date
Application number
HRP20160373TT
Other languages
English (en)
Croatian (hr)
Inventor
Joachim Maus
Beatrix Fyrnys
Torsten Hoffmann
Mario Weingart
Istvan Szelenyi
Peter Jürgen Cnota
Ullrich Munzel
Ursula Petzold
Original Assignee
Meda Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co. Kg filed Critical Meda Pharma Gmbh & Co. Kg
Publication of HRP20160373T1 publication Critical patent/HRP20160373T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HRP20160373TT 2005-03-16 2006-03-10 Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava HRP20160373T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66191805P 2005-03-16 2005-03-16
PCT/EP2006/002247 WO2006097250A1 (en) 2005-03-16 2006-03-10 The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases
EP06723360.1A EP1863476B1 (en) 2005-03-16 2006-03-10 The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
HRP20160373T1 true HRP20160373T1 (hr) 2016-05-06

Family

ID=36570797

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160373TT HRP20160373T1 (hr) 2005-03-16 2006-03-10 Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava

Country Status (18)

Country Link
US (1) US8268864B2 (https=)
EP (1) EP1863476B1 (https=)
JP (1) JP4991693B2 (https=)
CN (1) CN101128196B (https=)
AU (1) AU2006224842B2 (https=)
CA (1) CA2595791C (https=)
CY (1) CY1117571T1 (https=)
DK (1) DK1863476T3 (https=)
ES (1) ES2570332T3 (https=)
HR (1) HRP20160373T1 (https=)
HU (1) HUE027076T2 (https=)
MX (1) MX2007011273A (https=)
NO (1) NO340405B1 (https=)
NZ (1) NZ560206A (https=)
PL (1) PL1863476T3 (https=)
RU (1) RU2420285C2 (https=)
SI (1) SI1863476T1 (https=)
WO (1) WO2006097250A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
ATE403654T1 (de) * 2003-07-28 2008-08-15 Janssen Pharmaceutica Nv Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
LT1976828T (lt) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
ES2671874T3 (es) * 2007-10-18 2018-06-11 Rose U, Llc Formulaciones tópicas de glicopirrolato
KR20100072295A (ko) * 2007-10-25 2010-06-30 머크 프로스트 캐나다 리미티드 병용 요법
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
US9378456B2 (en) * 2012-11-19 2016-06-28 Microsoft Technology Licensing, Llc Task completion
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
ES3014615T3 (en) 2018-05-31 2025-04-23 Celltaxis Llc Method of reducing pulmonary exacerbations in respiratory disease patients
MA54707A (fr) * 2019-01-10 2021-11-17 Jiangyin Mucocare Pharmaceutical Co Ltd Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes
BR112022015199A2 (pt) * 2020-02-03 2022-10-11 Taro Pharma Ind Formulações tópicas de montelucaste
CN115792229B (zh) * 2022-01-28 2024-06-18 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0435038A (ja) * 1990-05-31 1992-02-05 Oki Electric Ind Co Ltd 半導体素子及びその製造方法
DE59410119D1 (de) 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
WO1998000016A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
CN100391942C (zh) * 1996-11-11 2008-06-04 索佛特克两合公司 对映异构纯的碱性芳基-环烷基-羟基羧酸酯,其制备方法及其在药品中的应用
WO1998048839A1 (en) * 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
WO1999062720A1 (fr) * 1998-05-29 1999-12-09 Citizen Watch Co., Ltd. Procede permettant de soumettre une imprimante a jet d'encre a un traitement de pre-utilisation
JP4672143B2 (ja) 1998-08-04 2011-04-20 ヤゴテック アーゲー 医薬用エーロゾル製剤
PL200941B1 (pl) * 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
SK288031B6 (sk) * 2000-10-31 2012-12-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Propellant-free liquid inhalation formulation
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
PT1372608E (pt) 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL158776A0 (en) 2001-05-25 2004-05-12 Pfizer A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
AU2002314102A1 (en) 2001-05-25 2002-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1369113B1 (en) * 2002-06-06 2006-11-22 CHIESI FARMACEUTICI S.p.A. Solubilisation of drugs in HFA propellant by means of emulsions
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
WO2004023984A2 (en) * 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
EP1569626A1 (en) * 2002-12-13 2005-09-07 Adagit Pharmaceutical porous particles
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
WO2004084896A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
JPWO2005055999A1 (ja) 2003-12-08 2007-07-05 日本新薬株式会社 抗コリン作用剤
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US8268864B2 (en) 2012-09-18
NO20075287L (no) 2007-12-05
CY1117571T1 (el) 2017-04-26
AU2006224842B2 (en) 2011-09-29
CA2595791C (en) 2013-10-08
EP1863476A1 (en) 2007-12-12
WO2006097250A1 (en) 2006-09-21
HUE027076T2 (en) 2016-08-29
RU2007138270A (ru) 2009-04-27
CN101128196A (zh) 2008-02-20
US20060211729A1 (en) 2006-09-21
JP2008533072A (ja) 2008-08-21
ES2570332T3 (es) 2016-05-17
EP1863476B1 (en) 2016-02-03
NO340405B1 (no) 2017-04-18
AU2006224842A1 (en) 2006-09-21
DK1863476T3 (en) 2016-05-17
NZ560206A (en) 2009-09-25
RU2420285C2 (ru) 2011-06-10
SI1863476T1 (sl) 2016-05-31
HK1114013A1 (en) 2008-10-24
CN101128196B (zh) 2013-01-02
CA2595791A1 (en) 2006-09-21
PL1863476T3 (pl) 2016-07-29
JP4991693B2 (ja) 2012-08-01
MX2007011273A (es) 2007-11-08

Similar Documents

Publication Publication Date Title
HRP20160373T1 (hr) Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava
HRP20200260T1 (hr) Pripravci, postupci i sustavi za respiratornu isporuku dva ili više aktivnih sredstava
CY1108978T1 (el) Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες
JP2007520508A5 (https=)
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
JP2010132695A5 (https=)
RU2016140347A (ru) Аэрозольные фторхинолоны и их применения
SI2928889T1 (en) COMPOUNDS WITH ACTIVITY OF ANTAGONIST OF MUSCARIN RECEPTORS AND BETA2 AGENTIST ADRENERGY RECEPTORS
RU2006132036A (ru) Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
JP2011520911A5 (https=)
HRP20120832T1 (hr) Antagonisti muskarinskih acetilkolinskih receptora
JP2019517597A5 (https=)
RU2006132038A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
HRP20130052T1 (hr) Lijeäśenje respiratorne bolesti
JP2008533072A5 (https=)
BRPI0606283A2 (pt) formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
HRP20100104T1 (hr) Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide
PE20091672A1 (es) Nueva dosificacion y formulacion
RU2006132040A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
BRPI0508170A (pt) formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem
Cha et al. Inhalation therapy in horses
JP2007520507A5 (https=)
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
ES2610104T3 (es) Aclidinio para el uso en la mejora de la calidad del sueño en pacientes con enfermedades respiratorias